• FirefoxInstall the new Firefox »
  •  Dow Down0.87% Nasdaq Down0.50%

    Relypsa, Inc. (RLYP)

    41.46 Down 0.25(0.60%) 11:10AM EST - Nasdaq Real Time Price
    Add to Portfolio
    ProfileGet Profile for:
    Relypsa, Inc.
    100 Cardinal Way
    Redwood City, CA 94063
    United States - Map
    Phone: 650-421-9500
    Website: http://www.relypsa.com

    Index Membership:N/A
    Full Time Employees:99

    Business Summary 

    Relypsa, Inc., a pharmaceutical company, focuses on the development and commercialization of non-absorbed polymeric drugs to treat disorders in the areas of renal, cardiovascular, and metabolic diseases in the United States. The company’s principal product candidate includes Patiromer, a non-absorbed potassium binder that completed Phase 3 clinical trial for the treatment of hyperkalemia. It also offers RLY6002, a pre-clinical product candidate that evaluates as an adjunct to diet and exercise to enhance glycemic control in adults with type 2 diabetes mellitus. The company was founded in 2007 and is headquartered in Redwood City, California.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Relypsa, Inc.

    Corporate Governance 
    Relypsa, Inc.’s ISS Governance QuickScore as of Mar 1, 2015 is 8. The pillar scores are Audit: 2; Board: 9; Shareholder Rights: 9; Compensation: 5.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
    Mr. John A. Orwin , 50
    Chief Exec. Officer, Pres and Director
    Dr. Gerrit Klaerner Ph.D.,
    Ms. Claire J. Lockey , 62
    Sr. VP of Pharmaceutical Devel. & Regulatory Affairs
    Dr. Lance Berman M.D., M.S, 44
    Chief Medical Officer and Sr. VP
    Ms. Kristine M. Ball , 43
    Chief Financial Officer, Principal Accounting Officer and Sr. VP
    Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders